Evelo Biosciences Inc

NASDAQ:EVLO  
2.16
-0.05 (-2.26%)
Earnings Announcements

Evelo Biosciences Reports Third Quarter 2022 Financial Results, Business Highlights

Published: 11/14/2022 22:46 GMT
Evelo Biosciences Inc (EVLO) - Evelo Biosciences Reports Third Quarter 2022 Financial Results and Business Highlights.
As of September 30, 2022, Cash and Cash Equivalents Were $69.1 Million.
Qtrly Net Loss per Share Attributable to Common Stockholders, Basic and Diluted $0.28.
Q3 Earnings per Share View $-0.33 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.28

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.18

More details on our Analysts Page.